Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC)
(2007) In Endocrine-Related Cancer 14(1). p.81-90- Abstract
- We set out to study the relationship between circulating levels of IGF-I and its major binding protein (IGFBP-3) in relation to ovarian cancer risk. We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. Levels of IGF-I and IGFBP-3 were measured in prediagnostic serum samples of 214 women who subsequently developed ovarian cancer, and 388 matched control subjects. Conditional logistic regression models were used to estimate relative risks of ovarian cancer by tertiles of IGF-I and IGFBP-3 levels. For all women, there was no association between the circulating IGF-I or IGFBP-3 levels and the risk of ovarian cancer. However, among women diagnosed with ovarian cancer aged 55 or... (More)
- We set out to study the relationship between circulating levels of IGF-I and its major binding protein (IGFBP-3) in relation to ovarian cancer risk. We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. Levels of IGF-I and IGFBP-3 were measured in prediagnostic serum samples of 214 women who subsequently developed ovarian cancer, and 388 matched control subjects. Conditional logistic regression models were used to estimate relative risks of ovarian cancer by tertiles of IGF-I and IGFBP-3 levels. For all women, there was no association between the circulating IGF-I or IGFBP-3 levels and the risk of ovarian cancer. However, among women diagnosed with ovarian cancer aged 55 or younger, the relative risk was higher in the middle or top tertiles of serum IGF-I, when compared with women in the lowest tertile (odds ratios (OR) = 1.8 (95%Cl 0.7-4.3) and OR = 2.4 (95%Cl 0.9-6.4); P-trend = 0.08) respectively. These results were adjusted for body mass index, previous hormone use, fertility problems, and parity. Restricting the analysis to women who were premenopausal at blood donation, relative risks for ovarian cancer diagnosed before age 55 were higher (OR = 5.1 (95%Cl 1.5-18.2) and OR = 5.6 (95%Cl 1.5-20.8) respectively, for second and third tertiles; P-trend = 0.02). Adjustment for serum IGFBP-3 levels only slightly attenuated relative risk estimates. Relations between IGFBP-3 and ovarian cancer before age 55 were in the same direction as for IGF-I, but less strong and statistically not significant. In women aged over 55, there was no association between serum IGF-I or IGFBP-3 and ovarian cancer risk. Our results suggest that the circulating levels of IGF-I may play a potentially important role in the development of ovarian cancer in women of a pre- or perimenopausal age. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/647775
- author
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Endocrine-Related Cancer
- volume
- 14
- issue
- 1
- pages
- 81 - 90
- publisher
- Society for Endocrinology
- external identifiers
-
- wos:000248344200007
- scopus:34249777562
- pmid:17395977
- ISSN
- 1479-6821
- DOI
- 10.1677/erc.1.01264
- language
- English
- LU publication?
- yes
- id
- 6a7869b8-ac92-4845-bbb4-aa4a0159d98e (old id 647775)
- date added to LUP
- 2016-04-01 12:05:56
- date last changed
- 2022-03-13 05:17:29
@article{6a7869b8-ac92-4845-bbb4-aa4a0159d98e,
abstract = {{We set out to study the relationship between circulating levels of IGF-I and its major binding protein (IGFBP-3) in relation to ovarian cancer risk. We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. Levels of IGF-I and IGFBP-3 were measured in prediagnostic serum samples of 214 women who subsequently developed ovarian cancer, and 388 matched control subjects. Conditional logistic regression models were used to estimate relative risks of ovarian cancer by tertiles of IGF-I and IGFBP-3 levels. For all women, there was no association between the circulating IGF-I or IGFBP-3 levels and the risk of ovarian cancer. However, among women diagnosed with ovarian cancer aged 55 or younger, the relative risk was higher in the middle or top tertiles of serum IGF-I, when compared with women in the lowest tertile (odds ratios (OR) = 1.8 (95%Cl 0.7-4.3) and OR = 2.4 (95%Cl 0.9-6.4); P-trend = 0.08) respectively. These results were adjusted for body mass index, previous hormone use, fertility problems, and parity. Restricting the analysis to women who were premenopausal at blood donation, relative risks for ovarian cancer diagnosed before age 55 were higher (OR = 5.1 (95%Cl 1.5-18.2) and OR = 5.6 (95%Cl 1.5-20.8) respectively, for second and third tertiles; P-trend = 0.02). Adjustment for serum IGFBP-3 levels only slightly attenuated relative risk estimates. Relations between IGFBP-3 and ovarian cancer before age 55 were in the same direction as for IGF-I, but less strong and statistically not significant. In women aged over 55, there was no association between serum IGF-I or IGFBP-3 and ovarian cancer risk. Our results suggest that the circulating levels of IGF-I may play a potentially important role in the development of ovarian cancer in women of a pre- or perimenopausal age.}},
author = {{Peeters, Petra H. M. and Lukanova, Annekatrin and Allen, Naomi and Berrino, Franco and Key, Tim and Dossus, Laure and Rinaldi, Sabina and van Gils, Carla H. and Bueno-de-Mesquita, H. Bas and Boeing, Heiner and Schulz, Mandy and Chang-Claude, Jenny and Linseisen, Jakob and Panico, Salvatore and Sacerdote, Carlotta and Palli, Domenico and Tumino, Rosario and Trichopoulou, Antonia and Trichopolos, Dimitrios and Bamia, Christina and Larranaga, Nerea and Ardanaz, Eva and Pera, Guillem and Ramon Quiros, J. and Martinez-Garcia, Carmen and Navarro, Carmen and Bingham, Sheila A. and Khaw, Kay-Tee and Clavel, Francoise and Tjonneland, Anne and Olsen, Anja and Overvad, Kim and Tetsche, Mette S. and Lund, Eiliv and Lundin, Eva and Berglund, Göran and Riboli, Elio and Kaaks, R.}},
issn = {{1479-6821}},
language = {{eng}},
number = {{1}},
pages = {{81--90}},
publisher = {{Society for Endocrinology}},
series = {{Endocrine-Related Cancer}},
title = {{Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC)}},
url = {{http://dx.doi.org/10.1677/erc.1.01264}},
doi = {{10.1677/erc.1.01264}},
volume = {{14}},
year = {{2007}},
}